Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer

Journal of Clinical Laboratory Analysis

Volumn 24, Issue 1, 2010, Pages 20-24

  Le Bricon, Thierry ^a   Gay Bellile, Cécile ^a   Cottu, Paul ^a   Benlakehal, Mourad ^a   Guillon, Hélène ^a   Houzé, Pascal ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast cancer; Chemotherapy; Isoenzymes; Metastases; Tumor markers

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALKALINE PHOSPHATASE INTESTINE ISOENZYME; ALKALINE PHOSPHATASE ISOENZYME; ALKALINE PHOSPHATASE LIVER ISOENZYME; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; NAVELBINE; TUMOR MARKER; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COLLAGEN DEGRADATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ELECTROPHORESIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LECTIN AFFINITY ELECTROPHORESIS; METASTASIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

ADULT; ALKALINE PHOSPHATASE; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN TYPE I; ELECTROPHORESIS; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL; WHEAT GERM AGGLUTININS;

EID: 75749123066     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20357     Document Type: Article

References (17)

1. Tanko LB, Karsdal MA, Christiansen C, Leeming DJ. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers? Cancer Metastasis Rev 2006;25:659.
2. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tanko LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers 2006;15:32.
3. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925.
4. Palma MA, Body JJ. Usefulness of bone formation markers in breast cancer. Int J Biol Markers 2005;20:146.
5. Moss DW. Alkaline phosphatase isoenzymes. Clin Chem 1982;28:2007.
6. Van Hoof VO, Van Oosterom AT, Lepoutre LG, De Broe ME. Alkaline phosphatase isoenzyme patterns in malignant disease. Clin Chem 1992;38:2546.
7. Gilles C, Moley M, Benlakehal M, Bousquet B, Le Bricon T. Séparation électrophorétique des isoenzymes de la phosphatase alcaline par le Kit Hydragel 15 Iso-PAL®. Immunoanalyse et Biologie spécialisée 2002;17:395.
8. Onica D, Sundblad L, Waldenlind L. Affinity electrophoresis of human serum alkaline phosphatase isoenzymes in agarose gel containing lectin. Clin Chim Acta 1986;155:285.
9. Houzé P, Bellik B, Extra JM, Bouro F, Bousquet B. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer. Clin Chim Acta 1999;281:77
10. Houzé P, Djerad A, Cottu PH, Bouro F, Bousquet B. Dosage sérique du C-télopeptide du collagéne de type I: Intérêt dans le suivi des métastases osseuses du cancer du sein. Immunoanalyse et Biologie Spécialisée 2000;15:414.
11. Wichers M, Schmidt E, Bidlingmaier F, Klingmuller D. Diurnal rythm of Crosslaps in human serum. Clin Chem 1999;45:1858.
12. Pectasides D, Farmakis D, Nikolaou M, et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 2005;37:171.
13. Leeming DJ, Hegele A, Byrjalsen I, et al. Biochemical markers for monitoring response to therapy: Evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008;17:1269.
14. Lüftner D, Richter A, Geppert R, Wernecke KD, Possinger K. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 2003;23:1017.
15. Koizumi M, Takahashi S, Ogata R. Bone metabolic marker in bone metastasis of breast cancer. Int J Clin Oncol 1999;4:241.
16. Generali DG, Tedoldi S, Tampellini M, et al. Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects. J Clin Oncol 2005;23:737.
17. Kailajärvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004;24:1271.